Pulling SEC filings + quote and writing the call…

Kiniksa Pharmaceuticals International, plc
Next earnings Jul 27, 2026 · consensus $0.31 EPS, $230M rev
Last earnings +23.5% on 2026-04-28
Revenue grew 60.1% YoY; but rich valuation (P/E 75.9).
Sources: SEC EDGAR (CIK 0001730430, latest 10-Q filed 2026-04-28) · EODHD · as of 6/25/2026, 8:35:27 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Middling fundamentals and a rich price (~50% above fair value) leave little margin of safety — a wait-and-see.
Kiniksa Pharmaceuticals International, plc shows $678M in FY2025 revenue (+60.1% YoY), a 8.7% net margin, and 10.4% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $38.5M | $220M | $270M | $423M | $678M |
| Gross profit | — | — | — | — | — |
| Operating income | -$157M | $9.77M | -$25.2M | -$45.6M | $77.2M |
| Net income | -$158M | $183M | $14.1M | -$43.2M | $59.0M |
| Diluted EPS | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 |
| Net margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1071 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-06-01 | Patel Sanj K CHAIRMAN & CEO | Acquired (C) | 900K | |
| 2026-05-29 | Quart Barry D Director | Exercise | 2.80K | |
| 2026-05-29 | Popovits Kimberly J Director | Exercise | 2.80K | |
| 2026-05-29 | McCain Tracey L Director | Exercise | 2.80K | |
| 2026-05-29 | Malley Thomas Director | Exercise | 2.80K | |
| 2026-05-29 | Levy Richard S Director | Exercise | 2.80K | |
| 2026-05-29 | Cole G Bradley Director | Exercise | 2.80K | |
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Award | 6.08K | |
| 2026-05-29 | BAKER BROS. ADVISORS LP Director | Award | 6.08K |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.